Impact of CD34/CD309 expression in circulating endothelial progenitor cells on prognosis and response to bortezomib therapy in multiple myeloma
- 13 August 2024
- journal article
- Published by Taylor & Francis in Journal of Immunoassay and Immunochemistry
- Vol. 45 (5) , 481-491
Abstract
Multiple myeloma (MM) is a prevalent yet incurable hematologic malignancy. Despite the proven efficacy of proteasome inhibitors in treating MM, resistance to Bortezomib-based treatments persists in a subset of patients. This case control study explores the potential of circulating endothelial progenitor cells (EPCs) as biomarkers for predicting response to Proteasome Inhibitor based therapy combined with Dexamethasone in MM patients. This study was conducted on 105 MM patients receiving bortezomib plus dexamethasone therapy and 90 healthy individuals as a control group. Utilizing 8-color multi-parameter flow cytometry, we assessed the levels of circulating EPCs, identified through CD34 FITC and CD309 PE markers at diagnosis and after one treatment cycle (4 weeks). Our findings revealed that patients exhibiting poor response to therapy showed significantly higher CD34/CD309 values than those with a good response (p < 0.001). The delineation of response based on CD34/CD309 expression was established with a cutoff ≤ 0.9 for percentage (yielding 100% sensitivity and 94.1% specificity) and ≤ 12.5 for absolute value (also with 100% sensitivity and 94.1% specificity). These results underscore the potential of EPC population levels, as quantified by CD34/CD309, to serve as a predictive biomarker for immunomodulatory treatment in MM patients undergoing Proteasome Inhibitor and Dexamethasone therapy.Keywords
This publication has 27 references indexed in Scilit:
- Multiple myeloma with high-risk cytogenetics and its treatment approachInternational Journal of Hematology, 2022
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaLeukemia, 2022
- Age Demographics of Subjects Enrolled in Global, Interventional Phase 3 Melanoma Clinical TrialsTherapeutic Innovation & Regulatory Science, 2022
- Comprehensive phenotyping of endothelial cells using flow cytometry 1: MurineCytometry Part A, 2020
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersThe Lancet Oncology, 2019
- Multiple Myeloma as a Model for the Role of Bone Marrow Niches in the Control of Angiogenesis2015
- Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network studyAmerican Journal of Hematology, 2014
- Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease☆European Journal of Cardio-Thoracic Surgery, 2010
- HEMATOPOIESIS AND CYTOKINESHematology/Oncology Clinics of North America, 2000
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995